Catalyst Pharmaceutical Partners (CPRX) announced after the bell Monday that both co-primary endpoints, as well as a secondary endpoint, in its Phase 3 clinical trial of Firdapse demonstrated that Firdapse was significantly superior to placebo. The stock is now up 0.58 after the bell.
Catalyst Pharmaceutical Partners moved in a narrow range throughout Monday's session and closed up by 0.01 at $2.99.
For comments and feedback contact: editorial@rttnews.com
Business News